Novo Nordisk and Lifera sign Memorandum of Understanding to enable the local production of semaglutide GLP-1 treatments in Saudi Arabia
Riyadh, Saudi Arabia – Novo Nordisk, a leading global healthcare company, today announced the signing of a Memorandum of Understanding (MOU) with Lifera, a biopharmaceutical company owned by the Saudi Public Investment
